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Introduction of SeqNet.org
SeqNet.org is currently an initiative of 44 laboratories from 25 
European countries and one laboratory from Lebanon (Table 1), 
founded in 2004, in collaboration with the Robert Koch Institute 
at the University of Münster, Germany (http://www.SeqNet.org). 
Since then, its main objective is to establish a European network 
of excellence for sequence-based typing of microbial pathogens, 
having its main focus on Staphylococcus aureus [1]. SeqNet.
org comprises a large number of national reference laboratories 
as well as university laboratories. The principle goal of SeqNet.
org is to generate unambiguous, easily comparable typing data in 
electronic, portable form to be used by infection control at a local 
level as well as national and European surveillance of sentinel micro-
organisms, such as methicillin-resistant Staphylococcus aureus 
(MRSA). spa-typing has been shown to be a useful tool in molecular 
hospital epidemiology [2,3]. Veterinary laboratories have recently 
joined the SeqNet.org initiative as MRSA has become an emerging 
problem in veterinary medicine [4,5]. spa-typing data from human 
and veterinary medicine can be compared using the spa server 
database [6].
SeqNet.org objectives
1. Organisation and participation in seven international workshops 
contributed to the harmonisation of sequencing methods for 
sequence-based typing of MRSA and the capacity for building 
DNA sequencing in diagnostic microbiology. Further meetings 
and workshops are planned. 
2. SeqNet.org rules require that SeqNet.org laboratories (Table 1) 
undergo at least one certification trial [7] for sequence-based 
typing of MRSA. Regular proficiency tests are foreseen. 
3. Curatorship of the Ridom spa server and the development and 
maintenance of a SeqNet.org web-portal allows the transfer of 
data at an international level. 
4. The excellence of data quality needs to be maintained. This is 
necessary as the access to the spa server will be enlarged in 
the future. 
SeqNet.org database
SeqNet.org is co-ordinated by the University Hospital in Münster 
and the Robert Koch Institute in Wernigerode, Germany. Besides 
ensuring the quality aspect, SeqNet.org is responsible for curating 
the spa server for all laboratories using the spa server. Currently, the 
44 SeqNet.org participating European laboratories (Table 1, Figure) 
and 148 other laboratories submitting data have synchronised more 
than 3,816 spa types consisting of 222 spa repeats from 59,401 S. 
aureus strains of which 93% were MRSA. The analysis of more than 
27,000 spa server submissions show that the 30 most frequent 
spa types cover 66% of all submissions (Table 2). 
F i g u r e
Proportion of strain submissions with complete data set to the spa 
server, by country in Europe, SeqNet.org curated Ridom spa server, 
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T a b l e  1
SeqNet.org participating medical and veterinary laboratories and institutions (44 in Europe, one in Lebanon)
Nr Organisation Veterinary (V)Medical (M) Main contact person City Country
1 Institut für Hygiene, Mikrobiologie und Tropenmedizin M H. Mittermayer Linz Austria
2 Österreichische Agentur für Gesundheit und Ernährungssicherheit V F. Allerberger Wien Austria
3 ULB-Hopital Erasme-National Reference Laboratory for Staphylococci M M. Struelens Bruxelles Belgium
4 National Center of Infectious and Parasitic Diseases M T. Kantardjiev,
D. Nashev
Sofia Bulgaria
5 National Institute of Public Health M H. Zemlicková Prague Czech Republic
6 Clinical and Molecular Microbiology, Clinical Hospital Centre Zagreb M S. Kalenic
A. Budimir
Zagreb Croatia
7 Hvidovre Hospital M H. Westh 
(Advisory Board)
Hvidovre Denmark
8 Statens Seruminstitut M R. Skov Copenhagen Denmark
9 National Food Institute (DTU) V H. Hasman Copenhagen Denmark
10 National Public Health Institute M J. Varkila Helsinki Finland
11 Centre National de Référence des Staphylocoques M J. Etienne
H. Meugnier
Lyon France
12 Institute of Hygiene (1), University Hospital Muenster, Clinic for 
Periodontology (2), University Hospital Münster 
M A. W. Friedrich (1) (Co-ordinator)
A. Mellmann (1), D. Harmsen (2) 
Muenster Germany
13 Institute of Medical Microbiology, University Hospital Muenster M G. Peters,  
K. Becker
Muenster Germany
14 Institute of Hygiene and Microbiology, University of Wuerzburg M U. Vogel Wuerzburg Germany
15 Robert Koch Institute M W. Witte 
(Co-ordinator)
Wernigerode Germany
16 Charité – University Medicine Berlin M K. Weist Berlin Germany
17 Institute of Medical Microbiology and Hospital Hygiene, University 
Hospital Düsseldorf
M R. Schulze-Röbbecke Düsseldorf Germany
18 Institut für Medizinische Mikrobiologie und Hygiene, University 
Hospital Tübingen
M V. Kempf, B. Schulte Tübingen Germany
19 University of Athens M A. Tsakris
E. Piperaki
Athens Greece
20 “Johan Bela” National Center for Epidemiology M M. Fuzi Budapest Hungary
21 Microbiology Research Unit, Division of Oral Biosciences, Dublin 
Dental School & Hospital
M A. Shore Dublin Ireland
22 National MRSA Reference Laboratory, St James’s Hospital, Dublin M A. Rossney Dublin Ireland
23 Istituto Superiore de Sanità, National Reference Laboratory on 
Antimicrobial Resistance
M A. Pantosti,  
M. Monaco
Rome Italy
24 Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana, 
National Reference Laboratory on Antimicrobial Resistance
V A. Battisti,  
R. Lorenzetti
Rome Italy
25 P. Stradins Clinical University Hospital M E. Miklasevicz Riga Latvia
26 Lebanese  American  University, Microbiology & Biotechnology M S. Tokajian Byblos Lebanon
27 Laboratoire National de Santé, Microbiology unit M J. Mossong Luxembourg Luxembourg
28 Laboratorium Microbiologie Twente Achterhoek M R. Hendrix Enschede The Netherlands
29 National Institute of Public Health (RIVM) M X. Huijsdens Bilthoven The Netherlands
30 University Hospital M E. Stobberingh Maastricht The Netherlands
31 St. Olavs University Hospital, National Reference Laboratory M T.  Jacobson Trondheim Norway
32 Akershus University Hospital M T. Taennes Lørenskog Norway
33 Telelab M Y. Tveten Skien Norway
34 National Medicines Institute M W. Hryniewicz 
(Advisory Board)
Warsaw Poland
35 Instituto de Tecnologia Quimica e Biologica (ITQB) M H. de Lencastre 
(Advisory Board)
Oeiras Portugal
36 National Intitute for Research and Development for Microbiology and 
Immunology
M I. Codita Bucharest Romania
37 Microbiology Department, Stobhill Hospital M D. Morrison
E. Giles
Glasgow Scotland
38 University of Ljubljana/Medial Faculty M M. Mueller-Premru Ljubljana Slovenia
39 Centro Nacional de Microbiología 
(Instituto de Salud Carlos III)
M J. Campos Madrid Spain
40 Lund University Hospital M A.-C. Petersson Lund Sweden
41 Swedish Institute for Infectious Disease Control 
(Smittskyddsinstitutet)
M S. Haeggman Solna Sweden
42 Sahlgrenska University Hospital, Göteborg M Ch. Welinder-Olsson Goteborg Sweden
43 Universitätsspital Basel, Mikrobiologie M R. Frei Basel Switzerland
44 Staphylococcus Reference Laboratory, Health Protection Agency M A. Kearns London UK
45 Health Protection Agency, Laboratory of Healthcare Associated 
Infection and HARMONY IUMS co-ordinator
M B. Cookson London UK
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Since 2006, the analysis with the BURP (Based Upon Repeat 
Pattern) algorithm makes it possible to group the spa types by 
means of their relatedness to each other and to a common founder 
[8,9]. Occasionally, misclassifications between Multilocus Sequence 
Typing (MLST) and spa occur due to intergenomic recombination 
[10,11] or large chromosomal replacement comprising the spa 
locus, leading to outliers, such as described for ST239 and ST34 
[12]. However, BURP analysis shows a correspondence of 92% for 
pulsed-field gel electrophoresis (PFGE) patterns and 97% for MLST 
clonal clusters, so that spa-typing generated within the SeqNet.
org network are comparable with PFGE and MLST databases 
[10,11]. For example, MRSA strains belonging to MLST type 
ST398 have been recently associated with pigs. They correspond 
to the spa Clonal Complex t011 (spa types t011, t034, t108) 
and these spa types can be used as identifying markers for such 
strains isolated from humans and animals [5]. The spa database 
is, in its current form, essentially used as a dictionary assuring a 
common nomenclature, providing molecular typing data in real 
time, and maintaining excellence of typing data quality. Its data on 
frequencies of spa types can already at this stage provide valuable 
information regarding wider geographical dissemination (Table 1, 
Figure). In interpreting raw spa data from the spa database the 
following aspects need to be considered:
• Different sampling schemes in different countries. Specifically, 
a few types might be overrepresented because of focussing on 
special topics such as: 1) pig farming and MRSA ST398 in 
Germany, the Netherlands, and Belgium; 2) Panton-Valentine 
leukocidin-positive (PVL-positive) t044 (ST80) looking especially 
for presumptive community-acquired CA-MRSA of the European 
clone; and 3) t084 due to a detailed study on dissemination of 
MRSA ST8/ spa t084 in Denmark. Furthermore, the same spa 
type can designate MRSA and MSSA (methicillin-sensitive S. 
aureus) isolates. Therefore, resistance must always be confirmed 
before.
• Geographical dissemination. Reporting particular types from 
many countries is an indicator for epidemic spreading, but it 
does not necessarily indicate wide geographical dissemination 
of a special clone. Here, a convergent evolution from a frequent 
MSSA ancestor is also possible, as already indicated by the 
possession of different types of SCCmec elements as in t002 
(ST5) and t008 (ST8). 
• Confirmation with additional testing. Identification of CA-MRSA 
ST8 (“USA300” clone) is likely when the isolates originate from 
deep infections of skin and soft tissue [13]. A confirmation of 
CA-MRSA ST8 should be performed by using PCR for lukS-PV 
lukF-PV and arcA. Therefore, spa-typing can be useful as 
surrogate marker for highly epidemic and highly prevalent 
clones [14], but further microbiological characterisation is 
necessary [11].
Recent developments 
In April 2007, the SeqNet.org plenary meeting was held in 
Rhodes, Greece and was aimed to exchange experiences, discuss 
and decide on questions which arose during the last three years of 
sequence-based typing throughout Europe. SeqNet.org participating 
laboratories presented their experiences in using spa-typing as 
T a b l e  2
Ten most frequently synchronised spa types on the SeqNet.org curated Ridom spa server, 59,401 submissions, 1 April 2004 - 6 May 2008 
spa-
type Frequency Countries of origin spa-CC MLST Comment and other designations
t003 12.64 % Austria, Belgium, Croatia, Czech Republic, Denmark, France, Germany, Netherlands, Norway, Sweden, Switzerland, United States CC001
ST-5,  
ST-225
CC5, Rhine Hesse MRSA (subclone), 
EMRSA-3, New York clone
t032 9.78 %
Austria, Belgium, Czech Republic, Denmark, France, Germany, Iceland, 
Italy, Lebanon, Netherlands, Norway, Spain, Sweden, Switzerland, 
United Kingdom, United States
CC032 ST-22 Barnim MRSA (prototype & subclone), EMRSA-15*, prototype of ST-22, CC22
t008 6.94 %
Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, 
Estonia, Finland, France, Germany, Iceland, India, Israel, Italy, Japan, 







CC8, Northern German MRSA (subclone), 
USA300 ORSA IV (CA-MRSA** in the US), 
Archaic/Iberian, ST250 ORSA I
t002 5.99 %
Austria, Belgium, China, Cyprus, Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Hungary, Iceland, Israel, Italy, Japan, 
Lebanon, Netherlands, Norway, Romania, Sweden, Switzerland, Taiwan, 
United Kingdom, United States
CC001 ST-5,  ST-231
CC5, Rhine Hesse MRSA (prototype), 
EMRSA-3*, New York clone, Japan clone, 
Pediatric, USA100 ORSA II, USA800 ORSA IV, 
ST 5 ORSA I
t037 3.32 %
Austria, Bulgaria, China, Croatia, Czech Republic, Denmark, France, 
Germany, Italy, Lebanon, Netherlands, Norway, Poland, South Africa, 





CC8/239, Vienna MRSA, Brazilian/
Hungarian, ST239 ORSA III, ST240 ORSA III, 
EMRSA-1*, -4, -7, -9, -11
t044 2.50 %
Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, 
France, Germany, Hungary, Italy, Lebanon, Netherlands, Norway, Spain, 
Sweden, Switzerland, United Kingdom
CC044 ST-80 CA-MRSA** (lukS-lukF +)  (CA-MRSA in Europe)
t011 2.19 % Austria, Belgium, France, Germany, Netherlands, Norway CC037 ST-398 Pig-associated clone
t001 2.12 %
Austria, Belgium, Croatia, Germany, Israel, Italy, Netherlands, 






CC5, Southern German MRSA (prototype & 
subclone), Rhine Hesse MRSA (subclone), 
EMRSA-3*,  
New York clone
t004 1.62 % Belgium, Denmark, Finland, France, Germany, Israel, Netherlands, Norway, Sweden, Switzerland, United States CC004 ST-45
CC45, Berlin MRSA (prototype), USA600 
ORSA II, USA600 ORSA IV
t015 1.45 %
Austria, Belgium, Croatia, Denmark, Finland, Germany, Indonesia, 
Italy, Latvia, Netherlands, Norway, Romania, South Africa, Spain, 
Sweden, Switzerland, Taiwan, United Kingdom
CC015 ST-45
* EMRSA = Epidemic methicillin-resistant Staphylococcus aureus
** CA-MRSA = Community-Acquired  methicillin-resistant Staphylococcus aureus
4  EUROSURVEILLANCE  Vol .  13 ·  Issues 4–6 ·  Apr–Jun 2008 ·  www.eurosurveillance.org
first line typing method, besides other typing methods, such as 
MLST and PFGE. In the following, the most important decisions 
of SeqNet.org plenary meeting are described.
External quality control standard and proficiency testing
Annual proficiency tests for all SeqNet.org participating 
laboratories will be performed. Currently only submission of single 
primer-based results are possible if excellent quality is ensured. 
Less than five edits are allowed, otherwise no synchronisation with 
the server is possible. With the existing quality criteria, 99.7% of 
all current submissions have the maximum quality value of 120 
out of 120 (excellent).
Spa server as a common strain pool
The spa server provides information on strains originating from 
various human and veterinary specimens isolated in countries all 
over Europe and other parts of the world. As it might therefore serve 
as a decentralised worldwide virtual strain collection, the server 
is programmed to be searchable for basic information (spa type, 
MRSA/MSSA, PVL, infection/colonisation, human/animal origin). 
An anonymous strain request system will be available in 2008.
Unique nomenclature
SeqNet.org maintains the curatorship of the spa server and is 
the gatekeeper for all bioinformatic tools using the spa server for 
synchronisation of data. Users of other spa-analysing software tools 
have the possibility to synchronise with the spa server, provided they 
fulfil all given quality criteria. Up to now, agreements have been 
achieved between SeqNet.org and two developers of spa-analysing 
softwares (Ridom: http://www.ridom.de and Applied Maths: http://
www.applied-maths.com). All users of the spa server are invited to 
perform the SeqNet.org certification and annual proficiency test. 
SeqNet.org membership, management, organisation and data flow 
and data property
As local and regional laboratories submit data to the spa server, 
this might lead to a bypassing of national reference laboratories (NRL) 
which are responsible for regional and especially national molecular 
surveillance and public health action. A technical software solution 
could make it possible that, upon mutual agreement between NRL 
and the local laboratories, all epidemiologically interesting spa-
typing data could be used in future by the NRL. National or regional 
data can be made visible by the national reference laboratory. Even 
cross-border, euregional data can be made visible as it has been 
done for regional networks such as EUREGIO MRSA-net Twente, 
Münsterland (http://www.mrsa-net.eu). Nevertheless, it remains up 
to national initiative to build up such national spa-typing networks. 
It is important to mention that all data on the spa server is strictly 
incrementally synchronised. This means that all synchronised data 
after having passed quality control and assignment of the spa type 
is stored with a single laboratory identifier. Every submitter using 
direct submission is able to withdraw his/her data at any time by 
re-synchronising with the server and indicating the deletion of the 
submission. Only the spa type and the information on quality will 
remain on the server. International study groups or regional and 
national networks can choose the option of not making visible their 
data submission (again, except spa type and quality) on the public 
homepage as long as they wish. In this way, data property of each 
single submitter is assured at any time.
Collaboration
There is collaboration with other European networks, such as the 
European Antimicrobial Resistance Surveillance System (http://www.
earss.nl). Most of the national reference laboratories are involved in 
both networks [15]. Furthermore, many members of the HARMONY 
IUMS are also members of SeqNet.org [16,17]. In 2007, SeqNet.
org started a collaboration with the Nosocomial Infection Control 
Consortium (INICC, http://www.inicc.org) in Argentina, a worldwide 
network for surveillance of nosocomial infections in developing 
countries. Most of these countries are interested in external quality 
control ring-trials for their national laboratories and seek assistance 
for typing methods. The collaboration with SeqNet.org can foster 
collaboration between epidemiologists and microbiologists in those 
countries.
Conclusion
The SeqNet.org initiative is a vivid European-wide network of 
laboratories for sequence-based typing of microbial pathogens, 
especially S. aureus. It generates high-quality typing data available 
to all participants and the public through the web-portal. The 
SeqNet.org laboratory network delivers the tools to detect local, 
national and international spread of MSSA and MRSA spa types. 
In particular, real-time synchronisation, automatic quality control 
and data property have made the SeqNet.org curatorship of the 
spa server successful for many years. In consequence, there is a 
strong need for EU-wide standardised sampling regimen to improve 
the use of spa type data for epidemiological purposes, such as 
the interpretation of relative frequencies, the time frame, and 
the geographical spread of S. aureus spa types. As the method is 
employed by both human and veterinary laboratories, typing results 
can already be used today for interdisciplinary epidemiological 
studies of MRSA. More laboratories from all parts of the world 
are welcome to join this initiative. If you are interested in joining 
SeqNet.org, please contact the coordinators.
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